$
14,233,822
$
11,767,668Contract support services837,598879,760Total revenues15,071,42012,647,428Operating expenses:Patient care expenses7,023,7226,438,563Cost of contract support services707,775727,477Provision for doubtful accounts1,003,462472,973Administrative expenses 5,100,0694,652,517Total operating expenses13,835,02812,291,530Income from operations1,236,392355,898Other income (expense):Interest income40,59432,374Other income38,98849,356Interest expense (80,332)(80,593)Total other income (expense), net(750)1,137Income before provision for income taxes1,235,642357,035Provision for income taxes 557,027133,431Net Income
$
678,615
$
223,604Basic net income per common share
$
0.03
$
0.01Basic weighted average number of shares outstanding19,532,09519,997,549Diluted net income per common share
$
0.03
$
0.01Diluted weighted average number of shares outstanding19,603,13820,141,989
'/>"/>
SOURCE PHC, Inc., d/b/a Pioneer Behavioral Health Copyright©2010 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 Related medicine technology :1.
Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients2.
EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer3.
Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain4.
ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer5.
DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,9476.
Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results7.
Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice8.
Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results9.
Amicus Therapeutics Announces Second Quarter 2007 Financial Results10.
Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights11.
MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study